Navigation Links
New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study
Date:10/6/2008

Data from SONIC Trial Showed REMICADE Therapy is More Likely to Induce

Steroid-Free Remission and Mucosal Healing Compared with Standard

Immunomodulator, Azathioprine

ORLANDO, Fla., Oct. 6 /PRNewswire/ -- Data presented for the first time from the Phase 3b Study of Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy (SONIC) may provide new insights into the approach to care of patients with moderate to severe Crohn's disease. According to findings from the SONIC trial, a significantly greater proportion of patients with moderate to severe Crohn's disease receiving REMICADE(R) (infliximab), either in combination with azathioprine or as monotherapy, experienced steroid-free remission and mucosal healing compared with patients receiving azathioprine alone. Azathioprine is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of Crohn's disease; however, it is widely used by gastroenterologists and other physicians in the United States to treat patients with Crohn's disease. Azathioprine is approved for the treatment of Crohn's disease in some countries outside the United States. Investigators reported that at week 26, 57 percent of patients receiving REMICADE combination therapy and 44 percent of patients receiving REMICADE monotherapy achieved steroid-free remission, the primary endpoint of the study, compared with 31 percent of patients receiving azathioprine alone (P < 0.001 REMICADE with azathioprine vs. azathioprine monotherapy; P = 0.009 REMICADE monotherapy vs. azathioprine monotherapy; P = 0.022 REMICADE with azathioprine vs. REMICADE monotherapy).

"Findings from the SONIC trial have the potential to challenge the treatment protocol for Crohn's disease as these data show that introducing REMICADE earlier may result in more patients achieving steroid-free remission and complete mucosal healing," said Dr. Jean-Frederic Colombel, Professor of Hepatogastroenterology
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. More Findings on Gene Involved in Childhood Asthma
2. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
3. VAI Findings Could Aid Diagnosis and Treatment of Several Types of Kidney Cancer
4. Findings on Bladder-Brain Link May Point to Better Treatments for Problems in Sleep, Attention
5. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
6. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
7. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
8. Study Findings Show Infection Control Intervention Helps Keep Kids in School
9. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
10. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
11. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  Synapse Biomedical Inc. ( www.synapsebiomedical.com ) ... the post-approval study of its NeuRx DPS® System ... meet the FDA enrollment requirement was implanted over ... The NeuRx DPS®, which is the only medical ... patients, is a humanitarian device that obtained approval ...
(Date:9/30/2014)... Sept. 30, 2014  eHealth, electronic access of ... access of this information, has become a major ... that has not translated into user-friendly, effective products. ... - http://photos.prnewswire.com/prnh/20140929/149123 For ... years developing MWD® Health Manager iEHR, a multilingual ...
(Date:9/30/2014)... Sept. 30, 2014 It is evident from the ... is not performing upto expectations due to the lack of ... with the intake of omega-3 fatty acids. Among omega-3 ingredient ... fish oil, attributed to the large vegetarian population in ... polyunsaturated fatty acid (PUFAs) ingredients is in growth stage of ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3MWD Challenges the Big eHealth Players With New Software for Your Smartphone 2Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2
... The 2009 Frost & Sullivan European Medical ... the radiology applications market is conferred on Viatronix ... the diagnostic imaging space. , (Logo: ... Viatronix has shown dedication to both developing and ...
... PAC, a leading global provider of advanced analytical instruments ... of the ANTEK MultiTek(TM) testing system for the fast, ... and halides. Industries include BioFuels, Chemicals, Food & Beverage, ... , "MultiTek(TM) is the only instrument on the ...
Cached Medicine Technology:Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 2Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 3Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 4New ANTEK MultiTek(TM) by PAC Provides Fast, All-in-One Testing for Sulfur, Nitrogen, Halides 2
(Date:9/30/2014)... 2014 issue of The FASEB Journal ... a simple blood test. This test, called the "lymphocyte genome ... than ever before, but it may eliminate the need for ... likely to develop cancer in the future. , "The ... peoples, lives," said Diana Anderson, a researcher involved in the ...
(Date:9/30/2014)... HealthDay Reporter MONDAY, Sept. 29, 2014 ... -- artificial valves, hip replacements, surgical mesh and the like ... after their approval by the U.S. Food and Drug Administration, ... prominent nonprofit groups and published online Sept. 29 in ... medical device testing on lax oversight by the FDA. ...
(Date:9/30/2014)... 30, 2014 Edward D. Buckingham, M.D., ... has been approved to be a director of a ... Reconstructive Surgery (AAFPRS) fellowship program. The announcement came last ... Florida. , The Educational and Research Foundation for the ... It represents the finest postgraduate program in the world ...
(Date:9/30/2014)... NC (PRWEB) September 30, 2014 ... and caring individuals, National Children’s Oral Health ... $150,000 in grants to non-profit clinical partners. ... Affiliate Network and deliver comprehensive educational, preventive ... , Recipients include:,     Just ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- Herceptin is ... cancer called HER2-positive and should remain the standard of ... findings from a long-term clinical trial. HER2-positive breast ... of breast cancer, according to the Mayo Clinic. ... countries received either Herceptin (trastuzumab) or Tykerb (lapatinib) in ...
Breaking Medicine News(10 mins):Health News:New blood test determines whether you have or are likely to get cancer 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3
... from UCSF examining HIV among men who have sex with men ... that a third of gay-identified men are infected with HIV. ... HIV and the community of men who have sex with men ... reserved for black South Africans during apartheid. The researchers ...
... BANNOCKBURN, Ill., Aug. 31 Omron Healthcare has announced a ... The achievement is part of a journey that began 36 years ... , , What has followed since 1973? The ... around the world. From PC compatible units which allow you to ...
... , , , ... Ingelheim today announced that results from the RE-LY(R) (Randomized Evaluation of ... atrial fibrillation (AF) outcomes trial ever conducted(1) (18,113 patients in 44 ... European Society of Cardiology Congress and published online in the ...
... ... care and non-medical caregiver services in Northern California and Utah, has been approved for ... its Haven Healthcare office in Layton, Utah , ... Walnut Creek, CA (PRWEB) August 29, 2009 -- Professional ...
... ... show and discusses how to integrate the color blue for to calm the body and ... and and professional communications. , ... (Vocus) August 29, 2009 -- ColorAlchemy is featured on HeartandHome radio show (heartandhomehealing.com/upcoming_shows.htm) and discusses ...
... were affected, study found , FRIDAY, Aug. 28 (HealthDay ... may determine their odds for progressing to AIDS-linked dementia, ... are a common hallmark of HIV infection. But during ... Sacktor noted that people in areas where HIV subtypes ...
Cached Medicine News:Health News:High HIV infection rate among Soweto Township gays 2Health News:And the Beat Goes on 2Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 2Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 3Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 4Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 5Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 6Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 7Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 8Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 9Health News:Professional Healthcare Is Approved for Medicare Licenses at Additional Offices in California and Utah 2Health News:ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 2Health News:ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 3Health News:ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 4
Remote Controlled, Easy to Use,Vision Tester Designed for Screening Children Ages 3 and Older.,Excellent for Pediatric and School Markets....
Contrast Sensitivity is Recognized as a Valuable Tool for Measuring Functional Vision Loss Caused by Early Eye Disease. Distance Test S.W.C.T. 201: Size 27in x 37 in (68.58cm x 93.98cm),Can be Wal...
Vision Testing for Infants and Non-Verbal Patients,Using Preferential Looking....
Adult: Letter Acuity, Astigmatic Clock, Binocular Balance, Supression, Fixation Disparity, Stereopsis...
Medicine Products: